8-KEarnings & ResultsExhibits & Filings

AMGEN INC 8-K Report, Financial Results (Apr 22, 2014)

Filed April 22, 2014For Securities:AMGN

Summary

Amgen Inc. filed an 8-K on April 22, 2014, to report its unaudited financial results for the first quarter ended March 31, 2014, and its financial condition as of that date. The filing incorporates a press release that details these results, including both GAAP and non-GAAP financial measures. Investors should note that the non-GAAP measures, such as adjusted earnings per share and free cash flow, are provided to offer additional insights into the company's performance and are reconciled to their GAAP equivalents within the press release. The primary purpose of this filing is to disclose the company's quarterly performance and financial position. While the information is provided, the filing explicitly states that it is furnished and not deemed "filed" for certain regulatory purposes, meaning it won't automatically be incorporated into future SEC filings unless specifically referenced. Investors should refer to the furnished press release for the detailed financial data and management's commentary on its significance.

Key Highlights

  • 1Amgen Inc. reported its unaudited results for the first quarter ended March 31, 2014.
  • 2The filing includes both GAAP and non-GAAP financial measures to provide a comprehensive view of performance.
  • 3Key non-GAAP metrics disclosed include adjusted earnings per share (EPS), free cash flow, adjusted operating income, and adjusted tax rate.
  • 4Reconciliations between non-GAAP and GAAP financial measures are provided within the accompanying press release (Exhibit 99.1).
  • 5The press release offers management's perspective on why these non-GAAP measures are useful for investors.
  • 6The information furnished in this 8-K is not considered 'filed' for Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated into other SEC filings.
  • 7Michael A. Kelly, Acting Chief Financial Officer, signed the report.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Amgen Inc.'s unaudited financial results for the first quarter ended March 31, 2014, and its financial condition as of that date. It includes a press release that details these financial outcomes.

Yes, the filing incorporates a press release (Exhibit 99.1) that announces Amgen's unaudited results of operations for the three months ended March 31, 2014, and its financial position as of that date. Investors need to refer to the press release for the detailed figures.

Non-GAAP financial measures are financial metrics that exclude or include amounts different from the closest measure under GAAP. Amgen uses measures like adjusted earnings per share and free cash flow because management believes they provide useful information to investors by offering a different perspective on the company's financial condition and operational results, often by excluding certain items that may not be indicative of ongoing performance. Reconciliations to GAAP are provided.

No, the filing explicitly states that the information furnished in Item 2.02 of this Current Report, including the press release, shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise incorporated by reference into future SEC filings unless specifically stated.